Drug Trial Radar · NCT00081159
Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases
Last checked: Nov 19, 2026Latest source record: Nov 10, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Jul 2004
Primary completion
Sep 2014
Study completion Sep 2014
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Apr 8, 2004
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as goserelin and leuprolide may fight prostate cancer by stopping the adrenal glands from producing androgens. Drugs used in chemotherapy such as doxorubicin work in different ways to stop tumor cells from dividing so they stop growing or die. Zoledronate may prevent bone loss and stop the growth of tumor cells in bone. Radioactive substances such as strontium-89 may relieve bone pain associated with prostate cancer. It is not yet known whether hormone (androgen) ablation therapy and chemotherapy combined with zoledronate is more effective with or without strontium-89 in treating prostate cancer and bone metastases. PURPOSE: This randomized phase II trial is studying giving hormone ablation therapy, doxorubicin, and zoledronate together with strontium-89 to see how well it works compared to hormone ablation therapy, doxorubicin, and zoledronate alone in treating patients with androgen-dependent prostate cancer and bone metastases.
Conditions
- Metastatic Cancer
- Prostate Cancer
Interventions
Doxorubicin hydrochlorideDrug
Doxorubicin 20 mg/m\^2 is administered intravenously either over 15 to 30 minutes via a peripheral line or over 24 hours via a central line on days 1, 8, and 15 every 28 days for 2 cycles.
Goserelin acetateDrug
Leuprolide acetateDrug
Zoledronic acidDrug
4 mg given intravenously over 15 minutes every 28 days for a total of 6 doses.
orchiectomyProcedure
strontium chloride SrRadiation
1 dose of strontium-89 (4 millicurie (mCi) total dose) administered intravenously on the first day of treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: Up to 90 months with evaulation in 4 week intervals for up to 6 months of treatment, then follow up until disease progression
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
M.D. Anderson Cancer Center at Orlando
Orlando, Florida
CCOP - Wichita
Wichita, Kansas
M.D. Anderson Cancer Center at University of Texas
Houston, Texas
CCOP - Marshfield Clinic Research Foundation
Marshfield, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.